Because it may help in determining treatment strategies following CNS progression, this study aimed to investigate the radiographic and clinical characteristics of newly developed or progressed CNS metastases with crizotinib treatment compared to those with alectinib treatment for ALK‐positive NSCLC. The gene discussed is ALK; the disease is non-small cell lung carcinoma.